Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Revvity, Inc. Common Stock (NY:RVTY)

91.03 +1.71 (+1.91%)
Official Closing Price Updated: 7:00 PM EDT, Jun 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Revvity, Inc. Common Stock

< Previous 1 2 3 Next >
Revvity Introduces New IVD Reference Standards for Monitoring Oncology Diagnostic Testing Workflows
From Revvity
Via Business Wire
Revvity’s EUROIMMUN Unveils New Fully Automated Instrument for Specialty Testing
From Revvity
Via Business Wire
Revvity to Present at Upcoming Investor Conferences
From Revvity
Via Business Wire
Revvity Announces Financial Results for the First Quarter of 2025
From Revvity
Via Business Wire
Revvity Board Declares Quarterly Dividend
From Revvity
Via Business Wire
Revvity to Hold Earnings Call on Monday, April 28, 2025
From Revvity
Via Business Wire
Revvity Secures FDA Approval for Improved Automated Latent Tuberculosis Test
From Revvity
Via Business Wire
Revvity’s EUROIMMUN Receives CE Mark for Novel Measles Antibody Detection Assay
From Revvity
Via Business Wire
Revvity Expands Alliance with Genomics England to Drive Research into Newborn Genomic Sequencing in England
From Revvity
Via Business Wire
Revvity Wins Permanent Injunction Enforcing Agreements with Cloud Software Group
From Revvity
Via Business Wire
Revvity to Present at Upcoming Investor Conferences
From Revvity
Via Business Wire
Revvity Announces Financial Results for the Fourth Quarter and Full Year of 2024
From Revvity
Via Business Wire
Revvity Board Declares Quarterly Dividend
From Revvity
Via Business Wire
Revvity and Element Biosciences Collaborate to Advance Sequencing-based IVD Neonatal Testing
From Revvity
Via Business Wire
Revvity to Hold Earnings Call on Friday, January 31, 2025; Provides Update on Financial Performance
From Revvity
Via Business Wire
Revvity Announces FDA Clearance for First Automated Free Testosterone Test
From Revvity
Via Business Wire
Revvity to Present at J.P. Morgan Healthcare Conference
From Revvity
Via Business Wire
Revvity Broadens Relationship with Genomics England to Advance Genomics in the UK
From Revvity
Via Business Wire
Scale Biosciences and Revvity’s BioLegend Launch First-of-its-Kind Solution for High Parameter Protein Profiling of Single Cells
From Scale Biosciences
Via Business Wire
Revvity to Present at 7th Annual Evercore ISI HealthCONx Conference
From Revvity
Via Business Wire
Revvity to Host Investor Day and Updates Organizational Structure to Reflect Recent Transformation
From Revvity
Via Business Wire
Revvity Announces Financial Results for the Third Quarter of 2024
From Revvity
Via Business Wire
Revvity Board Declares Quarterly Dividend
From Revvity
Via Business Wire
Revvity Introduces Transcribe AI: Revolutionizing Data Entry in Clinical Laboratories
From Revvity
Via Business Wire
Revvity Highlights its Strong Progress on Sustainability and Workplace Culture in 2024 Impact Report
From Revvity
Via Business Wire
Revvity To Hold Earnings Call on Monday, November 4, 2024
From Revvity
Via Business Wire
Revvity's EUROIMMUN Launches Solution for Specific Typing of Alzheimer's Disease Associated APOE Gene
From Revvity
Via Business Wire
Revvity to Present at Upcoming Investor Conferences
From Revvity
Via Business Wire
Revvity Announces Financial Results for the Second Quarter of 2024
From Revvity
Via Business Wire
Revvity Board Declares Quarterly Dividend
From Revvity
Via Business Wire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.